Form 4: Travere Therapeutics CFO Sells Shares
Insider Transaction (Form 4)
Christopher R. Cline, CHIEF FINANCIAL OFFICER of Travere Therapeutics, Inc., sold 50,508 shares of common stock on September 15, 2026.
Summary
- Option exercise/conversion: acquired 20,000 Common Stock at $17.44 ($348,800) on September 15, 2026; holds 138,016 after (Direct).
- Open-market sale: disposed of 27,473 Common Stock at $62.00 ($1,703,241) on September 15, 2026; holds 110,543 after (Direct).
- Open-market sale: disposed of 20,735 Common Stock at $62.61 ($1,298,175) on September 15, 2026; holds 89,808 after (Direct).
- Open-market sale: disposed of 1,900 Common Stock at $63.69 ($121,004) on September 15, 2026; holds 87,908 after (Direct).
- Open-market sale: disposed of 400 Common Stock at $65.31 ($26,124) on September 15, 2026; holds 87,508 after (Direct).
- Option exercise/conversion: disposed of 20,000 Employee stock option (right to buy) on September 15, 2026 (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $3,148,544 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Christopher R. Cline — Officer (CHIEF FINANCIAL OFFICER)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-15 | Option exercise/conversion | Common Stock | 20,000 | $17 | $348.8K | 138,016 |
| 2026-09-15 | Open-market sale | Common Stock | 27,473 | $62 | $1.7M | 110,543 |
| 2026-09-15 | Open-market sale | Common Stock | 20,735 | $63 | $1.3M | 89,808 |
| 2026-09-15 | Open-market sale | Common Stock | 1,900 | $64 | $121.0K | 87,908 |
| 2026-09-15 | Open-market sale | Common Stock | 400 | $65 | $26.1K | 87,508 |
| 2026-09-15 | Option exercise/conversion | Employee stock option (right to buy) | 20,000 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-15 | Option exercise/conversion (20,000 shares) |
| 2026-09-15 | Open-market sale (27,473 shares) |
| 2026-09-15 | Open-market sale (20,735 shares) |
| 2026-09-15 | Open-market sale (1,900 shares) |
| 2026-09-15 | Open-market sale (400 shares) |
| 2026-09-15 | Option exercise/conversion (20,000 shares) |
Keywords
insider transaction, Form 4, TVTX, Travere Therapeutics, Inc., bearish, Christopher R. Cline
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.